A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Recruiting · NCT05512208 · Registry updated 2025-10-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, mucinous ovarian cancer, neoplasm, uterine disorder | Recruiting | Phase 2 | 2025-10-22 | NCT05512208 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Oklahoma | 146 |
| Verastem, Inc. | 24 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| AdventHealth | Orlando | United States | 29 |
| Louisiana State University Medical Center New Orleans | New Orleans | United States | 1 |
| Stephenson Cancer Center | Oklahoma City | United States | 2 |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | United States | 16 |